When advanced medicine meets effective policy, patients thrive. That vision informs GAfPA’s work in Asia, where some regulatory processes do not yet reflect the sophisticated nature of advanced medicine. The desire for patient safety and patient access drives GAfPA’s continued advocacy across the continent.
Across Asia, biologic medicines and biosimilars hold promise for patients suffering from chronic diseases. But Asia needs to bring them to market using trusted regulatory frameworks and approval processes.
To protect patient access, Asia’s policymakers must address the need for clear and consistent regulatory standards. GAfPA’s advocates work toward that goal and toward making the promise of innovative medicine available to patients across Asia.